Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 5/2011

01-10-2011 | Review

Cellular and molecular pathogenesis of systemic lupus erythematosus: lessons from animal models

Authors: Simanta Pathak, Chandra Mohan

Published in: Arthritis Research & Therapy | Issue 5/2011

Login to get access

Abstract

Systemic lupus erythematosus (SLE) is a complex disease characterized by the appearance of autoantibodies against nuclear antigens and the involvement of multiple organ systems, including the kidneys. The precise immunological events that trigger the onset of clinical manifestations of SLE are not yet well understood. However, research using various mouse strains of spontaneous and inducible lupus in the last two decades has provided insights into the role of the immune system in the pathogenesis of this disease. According to our present understanding, the immunological defects resulting in the development of SLE can be categorized into two phases: (a) systemic autoimmunity resulting in increased serum antinuclear and antiglomerular autoantibodies and (b) immunological events that occur within the target organ and result in end organ damage. Aberrations in the innate as well as adaptive arms of the immune system both play an important role in the genesis and progression of lupus. Here, we will review the present understanding - as garnered from studying mouse models - about the roles of various immune cells in lupus pathogenesis.
Appendix
Available only for authorised users
Literature
1.
Manderson AP, Botto M, Walport MJ: The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol. 2004, 22: 431-456. 10.1146/annurev.immunol.22.012703.104549.CrossRefPubMed
2.
3.
Licht R, van Bruggen MC, Oppers-Walgreen B, Rijke TP, Berden JH: Plasma levels of nucleosomes and nucleosome-autoantibody complexes in murine lupus: effects of disease progression and lipopolyssacharide administration. Arthritis Rheum. 2001, 44: 1320-1330. 10.1002/1529-0131(200106)44:6<1320::AID-ART224>3.0.CO;2-X.CrossRefPubMed
4.
Mevorach D, Zhou JL, Song X, Elkon KB: Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med. 1998, 188: 387-392. 10.1084/jem.188.2.387.PubMedCentralCrossRefPubMed
5.
Walport MJ: Lupus, DNase and defective disposal of cellular debris. Nat Genet. 2000, 25: 135-136. 10.1038/75963.CrossRefPubMed
6.
Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, Roubey RA, Earp HS, Matsushima G, Reap EA: Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med. 2002, 196: 135-140. 10.1084/jem.20012094.PubMedCentralCrossRefPubMed
7.
Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J: Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci USA. 2000, 97: 1184-1189. 10.1073/pnas.97.3.1184.PubMedCentralCrossRefPubMed
8.
Bickerstaff MC, Botto M, Hutchinson WL, Herbert J, Tennent GA, Bybee A, Mitchell DA, Cook HT, Butler PJ, Walport MJ, Pepys MB: Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med. 1999, 5: 694-697. 10.1038/9544.CrossRefPubMed
9.
Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, Loos M, Pandolfi PP, Walport MJ: Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet. 1998, 19: 56-59. 10.1038/ng0598-56.CrossRefPubMed
10.
Grammer AC, Dorner T, Lipsky PE: Abnormalities in B cell activity and the immunoglobulin repertoire in human systemic lupus erythematosus. Mol Pathol Autoimmune Dis. 2001, 2: 282-318.
11.
Shlomchik MJ, Madaio MP, Ni D, Trounstein M, Huszar D: The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med. 1994, 180: 1295-1306. 10.1084/jem.180.4.1295.CrossRefPubMed
12.
Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ: A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med. 1999, 189: 1639-1648. 10.1084/jem.189.10.1639.PubMedCentralCrossRefPubMed
13.
Chan OT, Sh lomchik MJ: Cutting edge: B cells promote CD8+ T cell activation in MRL-Fas(lpr) mice independently of MHC class I antigen presentation. J Immunol. 2000, 164: 1658-1662.CrossRefPubMed
14.
Wolf SD, Dittel BN, Hardardottir F, Janeway CA: Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med. 1996, 184: 2271-2278. 10.1084/jem.184.6.2271.PubMedCentralCrossRefPubMed
15.
Yin Z, Bahtiyar G, Zhang N, Liu L, Zhu P, Robert ME, McNiff J, Madaio MP, Craft J: IL-10 regulates murine lupus. J Immunol. 2002, 169: 2148-2155.CrossRefPubMed
16.
Watanabe R, Ishiura N, Nakashima H, Kuwano Y, Okochi H, Tamaki K, Sato S, Tedder TF, Fujimoto M: Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol. 2010, 184: 4801-4809. 10.4049/jimmunol.0902385.PubMedCentralCrossRefPubMed
17.
Llorente L, Richaud-Patin Y, García-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, Alcocer-Varela J, Grangeot-Keros L, Alarcón-Segovia D, Wijdenes J, Galanaud P, Emilie D: Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 2000, 43: 1790-1800. 10.1002/1529-0131(200008)43:8<1790::AID-ANR15>3.0.CO;2-2.CrossRefPubMed
18.
Kumar KR, Li L, Yan M, Bhaskarabhatla M, Mobley AB, Nguyen C, Mooney JM, Schatzle JD, Wakeland EK, Mohan C: Regulation of B cell tolerance by the lupus susceptibility gene Ly108. Science. 2006, 312: 1665-1669. 10.1126/science.1125893.CrossRefPubMed
19.
Shultz LD, Rajan TV, Greiner DL: Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency. Trends Biotechnol. 1997, 15: 302-307. 10.1016/S0167-7799(97)01060-3.CrossRefPubMed
20.
Hibbs ML, Tarlinton DM, Armes J, Grail D, Hodgson G, Maglitto R, Stacker SA, Dunn AR: Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell. 1995, 83: 301-311. 10.1016/0092-8674(95)90171-X.CrossRefPubMed
21.
Bolland S, Ravetch JV: Spontaneous autoimmune disease in Fc(gamma) RIIB-deficient mice results from strain-specific epistasis. Immunity. 2000, 13: 277-285. 10.1016/S1074-7613(00)00027-3.CrossRefPubMed
22.
Taylor DK, Ito E, Thorn M, Sundar K, Tedder T, Spatz LA: Loss of tolerance of anti-dsDNA B cells in mice overexpressing CD19. Mol Immunol. 2006, 43: 1776-1790. 10.1016/j.molimm.2005.11.003.CrossRefPubMed
23.
Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A: Activation of autoreactive B cells by CpG dsDNA. Immunity. 2003, 19: 837-847. 10.1016/S1074-7613(03)00323-6.CrossRefPubMed
24.
Hasegawa K, Hayashi T: Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB × NZWF1 mice. Lupus. 2003, 12: 838-845. 10.1191/0961203303lu483oa.CrossRefPubMed
25.
Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ: Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med. 2005, 202: 321-331. 10.1084/jem.20050338.PubMedCentralCrossRefPubMed
26.
Krieg AM, Vollmer J: Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev. 2007, 220: 251-269. 10.1111/j.1600-065X.2007.00572.x.CrossRefPubMed
27.
Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S: Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science. 2006, 312: 1669-1672. 10.1126/science.1124978.CrossRefPubMed
28.
Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999, 190: 1697-1710. 10.1084/jem.190.11.1697.PubMedCentralCrossRefPubMed
29.
Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH: TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000, 404: 995-999. 10.1038/35010115.CrossRefPubMed
30.
Peng SL, Craft J: T cells in murine lupus: propagation and regulation of disease. Mol Biol Rep. 1996, 23: 247-251. 10.1007/BF00351176.CrossRefPubMed
31.
Seery JP, Carroll JM, Cattell V, Watt FM: Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing interferon gamma in the epidermis. J Exp Med. 1997, 186: 1451-1459. 10.1084/jem.186.9.1451.PubMedCentralCrossRefPubMed
32.
33.
Haas C, Ryffel B, Le Hir M: IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice. J Immunol. 1997, 158: 5484-5491.PubMed
34.
Jacob CO, van der Meide PH, McDevitt HO: In vivo treatment of (NZB × NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med. 1987, 166: 798-803. 10.1084/jem.166.3.798.CrossRefPubMed
35.
Ozmen L, Roman D, Fountoulakis M, Schmid G, Ryffel B, Garotta G: Soluble interferon-gamma receptor: a therapeutically useful drug for systemic lupus erythematosus. J Interferon Res. 1994, 14: 283-284. 10.1089/jir.1994.14.283.CrossRefPubMed
36.
Kang HK, Liu M, Datta SK: Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol. 2007, 178: 7849-7858.CrossRefPubMed
37.
Li X: Act1 modulates autoimmunity through its dual functions in CD40L/BAFF and IL-17 signaling. Cytokine. 2008, 41: 105-113. 10.1016/j.cyto.2007.09.015.CrossRefPubMed
38.
Garrett-Sinha LA, John S, Gaffen SL: IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol. 2008, 20: 519-525. 10.1097/BOR.0b013e328304b6b5.CrossRefPubMed
39.
Hoffman RW: T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol. 2004, 113: 4-13. 10.1016/j.clim.2004.05.001.CrossRefPubMed
40.
Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR: Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum. 1998, 41: 1241-1250. 10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H.CrossRefPubMed
41.
Passero FC, Myers AR: Decreased numbers of monocytes in inflamatory exudates in systemic lupus erythematosus. J Rheumatol. 1981, 8: 62-68.PubMed
42.
Jin O, Sun L, Kavikondala S, Lau C: Innate immunity and systemic lupus erythematosus. APLAR J Rheumatol. 2006, 9: 359-364. 10.1111/j.1479-8077.2006.00229.x.CrossRef
43.
Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL, Earp HS, Matsushima GK: Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature. 2001, 411: 207-211. 10.1038/35075603.CrossRefPubMed
44.
Lu Q, Lemke G: Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science. 2001, 293: 306-311. 10.1126/science.1061663.CrossRefPubMed
45.
Zhu J, Liu X, Xie C, Yan M, Yu Y, Sobel ES, Wakeland EK, Mohan C: T cell hyperactivity in lupus as a consequence of hyperstimulatory antigenpresenting cells. J Clin Invest. 2005, 115: 1869-1878. 10.1172/JCI23049.PubMedCentralCrossRefPubMed
46.
Kilmon MA, Wagner NJ, Garland AL, Lin L, Aviszus K, Wysocki LJ, Vilen BJ: Macrophages prevent the differentiation of autoreactive B cells by secreting CD40 ligand and interleukin-6. Blood. 2007, 110: 1595-1602. 10.1182/blood-2006-12-061648.PubMedCentralCrossRefPubMed
47.
Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003, 197: 711-723. 10.1084/jem.20021553.PubMedCentralCrossRefPubMed
48.
Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE, Zychlinsky A: Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA. 2010, 107: 9813-9818. 10.1073/pnas.0909927107.PubMedCentralCrossRefPubMed
49.
Georgiev M, Agle LM, Chu JL, Elkon KB, Ashany D: Mature dendritic cells readily break tolerance in normal mice but do not lead to disease expression. Arthritis Rheum. 2005, 52: 225-238. 10.1002/art.20759.CrossRefPubMed
50.
Chen M, Wang YH, Wang Y, Huang L, Sandoval H, Liu YJ, Wang J: Dendritic cell apoptosis in the maintenance of immune tolerance. Science. 2006, 311: 1160-1164. 10.1126/science.1122545.CrossRefPubMed
51.
Fairhurst AM, Wandstrat AE, Wakeland EK: Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv Immunol. 2006, 92: 1-69.CrossRefPubMed
52.
Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O, Coffman RL: Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med. 2005, 202: 1131-1139. 10.1084/jem.20050914.PubMedCentralCrossRefPubMed
53.
Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD: Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 2005, 115: 407-417.PubMedCentralCrossRefPubMed
54.
Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U, Tough DF: Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol. 2006, 176: 2074-2078.CrossRefPubMed
55.
Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, Cerutti A: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol. 2002, 3: 822-829.PubMedCentralCrossRefPubMed
56.
Ceppellini R, Polli E, Celada F: A DNA-reacting f actor in serum of a patient with lupus erythematosus diffusus. Proc Soc Exp Biol Med. 1957, 96: 572-574.CrossRefPubMed
57.
Liang Z, Xie C, Chen C, Kreska D, Hsu K, Li L, Zhou XJ, Mohan C: Pathogenic profiles and molecular signatures of antinuclear autoantibodies rescued from NZM2410 lupus mice. J Exp Med. 2004, 199: 381-398. 10.1084/jem.20030132.PubMedCentralCrossRefPubMed
58.
Tsao BP, Ohnishi K, Cheroutre H, Mitchell B, Teitell M, Mixter P, Kronenberg M, Hahn BH: Failed self-tolerance and autoimmunity in IgG anti-DNA transgenic mice. J Immunol. 1992, 149: 350-358.PubMed
59.
Yung S, Chan TM: Anti-DNA antibodies in the pathogenesis of lupus nephritis--the emerging mechanisms. Autoimmun Rev. 2008, 7: 317-321. 10.1016/j.autrev.2007.12.001.CrossRefPubMed
60.
Sekine H, Watanabe H, Gilkeson GS: Enrichment of anti-glomerular antigen antibody-producing cells in the kidneys of MRL/MpJ-Fas(lpr) mice. J Immunol. 2004, 172: 3913-3921.CrossRefPubMed
61.
Waters ST, McDuffie M, Bagavant H, Deshmukh US, Gaskin F, Jiang C, Tung KS, Fu SM: Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis. J Exp Med. 2004, 199: 255-264. 10.1084/jem.20031519.PubMedCentralCrossRefPubMed
62.
Waters ST, Fu SM, Gaskin F, Deshmukh US, Sung SS, Kannapell CC, Tung KS, McEwen SB, McDuffie M: NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci. Clin Immunol. 2001, 100: 372-383. 10.1006/clim.2001.5079.CrossRefPubMed
63.
Mannik M, Merrill CE, Stamps LD, Wener MH: Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J Rheumatol. 2003, 30: 1495-1504.PubMed
64.
Li QZ, Xie C, Wu T, Mackay M, Aranow C, Putterman C, Mohan C: Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest. 2005, 115: 3428-3439. 10.1172/JCI23587.CrossRefPubMed
65.
Schiffer L, Sinha J, Wang X, Huang W, von Gersdorff G, Schiffer M, Madaio MP, Davidson A: Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol. 2003, 171: 489-497.CrossRefPubMed
66.
Heymann F, Meyer-Schwesinger C, Hamilton-Williams EE, Hammerich L, Panzer U, Kaden S, Quaggin SE, Floege J, Grone HJ, Kurts C: Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. J Clin Invest. 2009, 119: 1286-1297. 10.1172/JCI38399.PubMedCentralCrossRefPubMed
67.
Bagavant H, Deshmukh US, Wang H, Ly T, Fu SM: Role for nephritogenic T cells in lupus glomerulonephritis: progression to renal failure is accompanied by T cell activation and expansion in regional lymph nodes. J Immunol. 2006, 177: 8258-8265.CrossRefPubMed
68.
Bossù P, Neumann D, Del Giudice E, Ciaramella A, Gloaguen I, Fantuzzi G, Dinarello CA, Di Carlo E, Musiani P, Meroni PL, Caselli G, Ruggiero P, Boraschi D: IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci USA. 2003, 100: 14181-14186. 10.1073/pnas.2336094100.PubMedCentralCrossRefPubMed
69.
Ruger BM, Erb KJ, He Y, Lane JM, Davis PF, Hasan Q: Interleukin-4 transgenic mice develop glomerulosclerosis independent of immunoglobulin deposition. Eur J Immunol. 2000, 30: 2698-2703. 10.1002/1521-4141(200009)30:9<2698::AID-IMMU2698>3.0.CO;2-1.CrossRefPubMed
70.
Singh RR: IL-4 and many roads to lupuslike autoimmunity. Clin Immunol. 2003, 108: 73-79. 10.1016/S1521-6616(03)00145-1.CrossRefPubMed
71.
Krüger T, Benke D, Eitner F, Lang A, Wirtz M, Hamilton-Williams EE, Engel D, Giese B, Müller-Newen G, Floege J, Kurts C: Identification and functional characterization of dendritic cells in the healthy murine kidney and in experimental glomerulonephritis. J Am Soc Nephrol. 2004, 15: 613-621. 10.1097/01.ASN.0000114553.36258.91.CrossRefPubMed
72.
Fiore N, Castellano G, Blasi A, Capobianco C, Loverre A, Montinaro V, Netti S, Torres D, Manno C, Grandaliano G, Ranieri E, Schena FP, Gesualdo L: Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis. Mol Immunol. 2008, 45: 259-265. 10.1016/j.molimm.2007.04.029.CrossRefPubMed
73.
Monrad S, Kaplan MJ: Dendritic cells and the immunopa thogenesis of systemic lupus erythematosus. Immunol Res. 2007, 37: 135-145. 10.1007/BF02685895.CrossRefPubMed
74.
Hooke DH, Gee DC, Atkins RC: Leukocyte analysis using monoclonal antibodies in human glomerulonephritis. Kidney Int. 1987, 31: 964-972. 10.1038/ki.1987.93.CrossRefPubMed
75.
Schiffer L, Bethunaickan R, Ramanujam M, Huang W, Schiffer M, Tao H, Madaio MP, Bottinger EP, Davidson A: Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol. 2008, 180: 1938-1947.PubMedCentralCrossRefPubMed
76.
Triantafyllopoulou A, Franzke CW, Seshan SV, Perino G, Kalliolias GD, Ramanujam M, van Rooijen N, Davidson A, Ivashkiv LB: Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc Natl Acad Sci USA. 2010, 107: 3012-3017. 10.1073/pnas.0914902107.PubMedCentralCrossRefPubMed
77.
Fu Y, Du Y, Mohan C: Experimental anti-GBM disease as a tool for studying spontaneous lupus nephritis. Clin Immunol. 2007, 124: 109-118. 10.1016/j.clim.2007.05.007.CrossRefPubMed
78.
Holdsworth SR, Neale TJ, Wilson CB: Abrogation of macrophage-dependent injury in experimental glomerulonephritis in the rabbit. Use of an antimacrophage serum. J Clin Invest. 1981, 68: 686-698. 10.1172/JCI110304.PubMedCentralCrossRefPubMed
79.
Ikezumi Y, Hurst LA, Masaki T, Atkins RC, Nikolic-Paterson DJ: Adoptive transfer studies demonstrate that macrophages can induce proteinuria and mesangial cell proliferation. Kidney Int. 2003, 63: 83-95.CrossRefPubMed
80.
Moore KJ, Yeh K, Naito T, Kelley VR: TNF-alpha enhances colony-stimulating factor-1-induced macrophage accumulation in autoimmune renal disease. J Immunol. 1996, 157: 427-432.PubMed
81.
82.
Scapini P, Carletto A, Nardelli B, Calzetti F, Roschke V, Merigo F, Tamassia N, Pieropan S, Biasi D, Sbarbati A, Sozzani S, Bambara L, Cassatella MA: Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. Blood. 2005, 105: 830-837. 10.1182/blood-2004-02-0564.CrossRefPubMed
83.
Johnson RJ, Lovett D, Lehrer RI, Couser WG, Klebanoff SJ: Role of oxidants and proteases in glomerular injury. Kidney Int. 1994, 45: 352-359. 10.1038/ki.1994.45.CrossRefPubMed
84.
Baudeau C, Delarue F, He CJ, Nguyen G, Adida C, Peraldi MN, Sraer JD, Rondeau E: Induction of MHC class II molecules HLA-DR, -DP and -DQ and ICAM 1 in human podocytes by gamma-interferon. Exp Nephrol. 1994, 2: 306-312.PubMed
85.
Coers W, Brouwer E, Vos JT, Chand A, Huitema S, Heeringa P, Kallenberg CG, Weening JJ: Podocyte expression of MHC class I and II and intercellular adhesion molecule-1 (ICAM-1) in experimental pauci-immune crescentic glomerulonephritis. Clin Exp Immunol. 1994, 98: 279-286.PubMedCentralCrossRefPubMed
86.
Yokoyama H, Zheng X, Strom TB, Kelley VR: B7(+)-transfectant tubular epithelial cells induce T cell anergy, ignorance or proliferation. Kidney Int. 1994, 45: 1105-1112. 10.1038/ki.1994.147.CrossRefPubMed
87.
Tipping PG, Holdsworth SR: Cytokines in glomeruloneph ritis. Semin Nephrol. 2007, 27: 275-285. 10.1016/j.semnephrol.2007.02.002.CrossRefPubMed
88.
Li S, Kurts C, Kontgen F, Holdsworth SR, Tipping PG: Major histocompatibility complex class II expression by intrinsic renal cells is required for crescentic glomerulonephritis. J Exp Med. 1998, 188: 597-602. 10.1084/jem.188.3.597.PubMedCentralCrossRefPubMed
89.
Molano A, Lakhani P, Aran A, Burkly LC, Michaelson JS, Putterman C: TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis. Immunol Lett. 2009, 125: 119-128. 10.1016/j.imlet.2009.06.010.CrossRefPubMed
90.
Timoshanko JR, Sedgwick JD, Holdsworth SR, Tipping PG: Intrinsic renal cells are the major source of tumor necrosis factor contributing to renal injury in murine crescentic glomerulonephritis. J Am Soc Nephrol. 2003, 14: 1785-1793. 10.1097/01.ASN.0000073902.38428.33.CrossRefPubMed
Metadata
Title
Cellular and molecular pathogenesis of systemic lupus erythematosus: lessons from animal models
Authors
Simanta Pathak
Chandra Mohan
Publication date
01-10-2011
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2011
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3465

Other articles of this Issue 5/2011

Arthritis Research & Therapy 5/2011 Go to the issue

Research article

Effects of short-term glucocorticoid treatment on changes in cartilage matrix degradation and chondrocyte gene expression induced by mechanical injury and inflammatory cytokines

Research article

Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features

Research article

Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects

Research article

Quantification of the whole-body burden of radiographic osteoarthritis using factor analysis

Editorial

Use of administrative claims data for comparative effectiveness research of rheumatoid arthritis treatments

Review

Osteoimmunology and osteoporosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits